Skip to content
Triangle logo TriangleGet started
← Full study record

NCT05255601 · OUTCOME

Number of Participants With Adverse Events (AEs) Leading to Discontinuation - Part A

A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of Relatlimab Plus Nivolumab in Pediatric and Young Adults With Hodgkin and Non-Hodgkin Lymphoma · Source last updated 2026-06-26

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
COUNT_OF_PARTICIPANTS
Unit
Participants
Interval / dispersion
Not reported
Time frame
From first dose to 135 days post last dose (Up to approximately 11 months)

What was measured

An adverse event (AE) is defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a clinical investigation participant administered study treatment that does not necessarily have a causal relationship with this treatment.

Analysis population: All treated participants in part A

Groups in this outcome

Part A - Flat Dosing (AF)

Participants received treatment with Relatlimab 160 mg + Nivolumab 480 mg Q4W

Part A - Age/Weight-based Dosing (AW)

Participant received treatment with Relatlimab 2 mg/kg + Nivolumab 6 mg/kg Q4W

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Part A - Flat Dosing (AF)4
Part A - Age/Weight-based Dosing (AW)1

Reported measurements

Source class 1
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Part A - Flat Dosing (AF)0Not reportedNot reportedNot reportedNot reported
Part A - Age/Weight-based Dosing (AW)0Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        0
      2. group Id
        OG001
        value
        0
denoms
  1. counts
    1. group Id
      OG000
      value
      4
    2. group Id
      OG001
      value
      1
    units
    Participants
description
An adverse event (AE) is defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a clinical investigation participant administered study treatment that does not necessarily have a causal relationship with this treatment.
groups
  1. description
    Participants received treatment with Relatlimab 160 mg + Nivolumab 480 mg Q4W
    id
    OG000
    title
    Part A - Flat Dosing (AF)
  2. description
    Participant received treatment with Relatlimab 2 mg/kg + Nivolumab 6 mg/kg Q4W
    id
    OG001
    title
    Part A - Age/Weight-based Dosing (AW)
param Type
COUNT_OF_PARTICIPANTS
population Description
All treated participants in part A
reporting Status
POSTED
time Frame
From first dose to 135 days post last dose (Up to approximately 11 months)
title
Number of Participants With Adverse Events (AEs) Leading to Discontinuation - Part A
type
PRIMARY
unit Of Measure
Participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice